$48.95
2.70% yesterday
Nasdaq, Nov 25, 09:49 pm CET
ISIN
US47103J1051
Symbol
JANX
Sector
Industry

Janux Therapeutics Inc Stock price

$48.82
-4.59 8.59% 1M
+3.45 7.60% 6M
+38.09 354.99% YTD
+38.78 386.26% 1Y
+29.99 159.27% 3Y
+23.67 94.12% 5Y
+23.67 94.12% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-1.49 2.96%
ISIN
US47103J1051
Symbol
JANX
Sector
Industry

Key metrics

Market capitalization $2.56b
Enterprise Value $1.93b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 147.71
P/S ratio (TTM) P/S ratio 196.33
P/B ratio (TTM) P/B ratio 3.89
Revenue growth (TTM) Revenue growth 54.12%
Revenue (TTM) Revenue $13.05m
EBIT (operating result TTM) EBIT $-85.96m
Free Cash Flow (TTM) Free Cash Flow $-37.82m
Cash position $658.03m
EPS (TTM) EPS $-1.18
P/E forward negative
P/S forward 203.52
EV/Sales forward 153.11
Short interest 16.23%
Show more

Is Janux Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Janux Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Janux Therapeutics Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Janux Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Janux Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
13 13
54% 54%
100%
- Direct Costs 2.08 2.08
14% 14%
16%
11 11
65% 65%
84%
- Selling and Administrative Expenses 35 35
61% 61%
268%
- Research and Development Expense 60 60
3% 3%
458%
-84 -84
14% 14%
-643%
- Depreciation and Amortization 2.08 2.08
14% 14%
16%
EBIT (Operating Income) EBIT -86 -86
14% 14%
-659%
Net Profit -61 -61
3% 3%
-464%

In millions USD.

Don't miss a Thing! We will send you all news about Janux Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Janux Therapeutics Inc Stock News

Neutral
Business Wire
about 22 hours ago
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Host Virtual Event.
Positive
Seeking Alpha
7 days ago
Janux Therapeutics' TRACTr and TRACIr platforms show promise in targeting cancer cells while minimizing off-target effects and improving drug half-life. Lead candidate JANX007 demonstrates strong PSA reduction and favorable safety profile in phase 1 trials for metastatic castration-resistant prostate cancer. JANX007's innovative design addresses limitations of previous T cell engagers, showing ...
Neutral
Business Wire
20 days ago
SAN DIEGO--(BUSINESS WIRE)---- $JANX--3Q24 Earnings Release.
More Janux Therapeutics Inc News

Company Profile

Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in La Jolla, CA.

Head office United States
CEO David Campbell
Employees 64
Founded 2017
Website www.januxrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today